{"cluster": 65, "subcluster": 5, "abstract_summ": " A SARS-CoV receptor-binding domain (RBD) recombinant protein was developed and manufactured under current good manufacturing practices in 2016 . The protein, known as RBD219-N1 when formulated on Alhydrogel, induced high-level neutralizing antibodies and protective immunity with minimal immunopathology in mice after a homologous virus challenge ."}